DGAP-News: Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022
Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to 8.8 million in the first half of the 2022 financial year, compared to 5.8 million in the first half of the previous year.
- Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to 8.8 million in the first half of the 2022 financial year, compared to 5.8 million in the first half of the previous year.
- EBIT in the first half of the year 2022 mounted to - 9.1 million and was thus below the previous year's value of - 8.5 million.
- In the current half year, this includes expenses for the Biotest Next Level project in the amount of 41.5 million (same period of the previous year: 38.0 million).
- The Biotest Group's total earnings after tax in the first half of 2022 were -19.9 million (same period of the previous year: -18.2 million).